BRKR — Q2 2026 Financial Report Analysis

Margins jumped, orders improved — and a $135 million write-down turned the quarter into a loss

Bruker, the maker of high-end lab instruments (NMR magnets, mass spectrometers, electron and X-ray microscopy tools, microbiology diagnostics), grew second-quarter 2026 revenue 5.2% to $838.5 million. Stripping out currency moves and acquisitions, "organic" growth — the growth the existing business generated on its own — was 2.8%, Bruker's first organic increase after a weak first quarter (first-half organic revenue was still down 0.8%). On the company's preferred adjusted basis, operating margin rose from 9.0% to 14.1% and adjusted EPS from $0.32 to $0.49.

The GAAP (official accounting) picture is the opposite: a $(0.41) loss per share, versus $0.05 profit a year earlier. Almost all of the gap is a $134.9 million non-cash goodwill impairment — an admission that two businesses Bruker bought are worth less than it paid for them.

At a glance

• Adjusted operating margin 14.1%, up from 9.0%. Bruker credits cost cuts, a "positive net U.S. tariffs impact" (refunds of tariffs struck down by the Supreme Court in February) and a better sales mix. Part of that jump is a refund, not a repeatable saving.
• $134.9 million goodwill impairment. $98.4 million wipes out all goodwill in its lab-automation unit (Chemspeed Technologies) and $36.5 million hits Bruker Spatial Biology. It is non-cash, but it says the acquisitions are earning less than planned.
• Scientific Instruments bookings up 10% organically, book-to-bill above 1.0. Orders exceeded shipments, and the order backlog ("remaining performance obligations") rose to $2,775.6 million from $2,569.4 million at year-end. That is the best evidence for management's call that a recovery is starting.

Key figures

"n/m" means not meaningful: a change from a profit to a loss has no useful percentage.

Takeaway: The real story is the margin reset, not the loss. Segment operating profit rose 63% ($151.4M vs $93.0M) on 5% more revenue, which means Bruker's cost cuts are working. Some of that came from a one-time tariff refund, though, and Bruker still burned cash this quarter, so the second half has to show the gains holding up without that help.

Where the revenue came from

Bruker reported under four segments this quarter (it reorganized them after June 30; see below):

Segment margins are segment operating income divided by segment revenue, both from the 10-Q's segment note; segment figures exclude corporate costs, amortization and impairments.

• Customers: Bruker says Q2 organic growth came from "stronger demand in the biotechnology and pharmaceutical, hospital and clinical, and semiconductor markets," partly offset by "lower revenue from academic and government research markets." CEO Frank Laukien said US academic demand "remained soft," but academic and government bookings in Europe and China "were up strongly."
• CALID was the growth engine, helped by acquisitions as well as academic and biopharma demand. BioSpin's revenue was flat but its segment profit nearly doubled ($41.7M vs $23.1M) as cost of revenue fell $14.0 million.
• BEST grew on its superconductor business plus fusion-energy and high-energy-physics projects (per the first-half commentary).
• Geography: US revenue rose 11.4% to $248.2M and Europe rose 13.3% to $308.7M (helped by a weaker dollar; currency added 0.9 points to total growth). Asia Pacific fell 10.2% to $217.3M. China dropped 8.5% to $104.9M and is down 17.1% for the half ($178.9M vs $215.9M). The stronger Chinese academic orders the CEO describes have not yet turned into revenue.

What the headline numbers hide

• The GAAP loss is mostly an accounting write-down, but it's a meaningful one. Of the $183.8M gap between GAAP and adjusted operating income, $134.9M is the goodwill impairment, $33.3M is amortization of intangible assets from acquisitions, and the rest is restructuring, deal costs and asset write-downs. Bruker cut its forecast for Chemspeed (lab automation) and wrote off all its goodwill. Spatial Biology took the second charge after Bruker merged its Cellular Analysis business into it. The 10-Q warns that Spatial Biology's book value "now approximates its fair value," and that a 1-point increase in the discount rate, or about 10% less projected profit, could each reduce its estimated value by about 25%. More charges are possible in Q3: the July segment reorganization counts as a "triggering event," and Bruker must run another goodwill test in the third quarter.
• The tax line makes the loss look worse. Bruker recorded a $14.2M tax expense on a $40.7M pretax loss, because goodwill impairments are not tax-deductible.
• A one-off gain helped GAAP, and adjusted EPS correctly leaves it out. "Interest and other income" was +$24.6M, versus –$11.4M a year ago. That swing came mainly from a $27.6M unrealized gain on a stake in a company that went public in April (now worth $37.6M, with a lock-up that expires October 14, 2026). The adjusted figures exclude this gain, so the $0.49 isn't inflated by it.
• Tariff refunds flatter the margin. Bruker books approved refunds of the IEEPA tariffs it paid in 2025 and Q1 2026 as a reduction in cost of revenue, and most of its claims had been approved by June 30. It names the "positive net U.S. tariffs impact" as one of three reasons gross and operating margins expanded, but doesn't say how many dollars it was worth. This part of the margin gain won't come back once the refunds are collected. (The refunds also trimmed reported organic revenue growth: 2.8% including them, 3.4% excluding them.)
• Cash conversion was poor. Operating cash flow was –$77.4M in the quarter and –$6.2M for the half, against first-half adjusted net income of $122.6M. Free cash flow (operating cash minus capital spending) was –$106.2M for the quarter. Bruker cites legal settlement payments and "lower collections of accounts receivable." Cash fell to $184.9M from $298.8M at year-end, and Bruker drew a net $170M on its revolving credit line in Q2.
• Some of the savings came from research spending. R&D fell 5.9% to $94.3M. That raises margins now, but for a company that sells on technical leadership it is a cost worth watching.
• Preferred dividends sit between the company's profit and common shareholders. $10.9M of dividends on the mandatory convertible preferred stock is deducted before EPS. The adjusted EPS also reflects this cost.
• Adjusted EPS grew despite tax, not because of it. The adjusted tax rate rose to 25.0% from 23.6%, and the diluted share count barely moved (152.8M vs 151.7M), so the EPS gain came from operations, not buybacks or tax.

Outlook

Bruker kept its full-year 2026 guidance except for currency and tax:

• Revenue $3.54–3.57 billion, up 3–4% from $3.44 billion, with organic growth of 1–2%. Bruker now expects currency to add about 0.5%, down from 1.5% previously.
• Adjusted EPS $2.10–2.15, unchanged and up 15–17% from $1.83, now assuming a 27.5% adjusted tax rate and including about a $0.10 currency headwind.

The guidance assumes a strong second half. First-half adjusted EPS was $0.80, so Bruker needs roughly $1.30–1.35 in H2, versus about $1.05 in H2 2025 ($1.83 minus $0.78). That is about 24–29% growth. Organic revenue, down 0.8% in the first half, has to grow enough in H2 to land at +1–2% for the year. The order trend (BSI bookings +10%, backlog up 8% since December) supports the revenue side. The EPS side depends on cost savings holding up after the tariff refunds are used up. Laukien said he expects "significant organic margin expansion and non-GAAP EPS growth not only this year, but in 2027 as well."

What to watch in the Q3 report: results will be shown under the new segments (BSI Biosystems, a new Microbiology & Infection Diagnostics segment, NANO and BEST), so year-ago comparisons will be restated. Also watch whether the required Q3 goodwill test brings another impairment, whether China revenue starts to follow the stronger orders, and whether operating cash flow turns positive. For a company guiding to 15%+ EPS growth, cash flow is the clearest test of earnings quality.